» Articles » PMID: 32647978

Association of Bullous Pemphigoid and Comorbid Health Conditions: a Case-control Study

Overview
Specialty Dermatology
Date 2020 Jul 11
PMID 32647978
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Bullous pemphigoid is an autoimmune skin disease characterized by the formation of blisters between the epidermis and dermis. Comorbidities of pemphigoid have not been well-described. Identification of comorbidities associated with pemphigoid is important to decrease morbidity and mortality.

Objective: To identify the comorbid health conditions of bullous pemphigoid.

Methods: This was a case-control study of 91 cases of pemphigoid verified by clinical and laboratory diagnosis and 546 age- and sex-matched controls with complete follow-up at a large metropolitan quaternary care medical center.

Results: The average age of bullous pemphigoid patients was 76 years and 53% of patients were female. Forty-eight (53%) of the BP patients had a history of inpatient hospitalization, of which 22 (24.2%) were hospitalized for either previously undiagnosed BP or an exacerbation of BP. Bullous pemphigoid was significantly associated with hypertension [adjusted odds ratio (95% confidence interval)]: [2.03 (1.24-3.32)], diabetes mellitus [2.59 (1.60-4.19)], chronic kidney disease [2.29 (1.19-4.40)], end-stage renal disease [3.82 (1.48-9.85)], basal cell carcinoma of the skin [6.00 (1.94-18.6)], and obstructive sleep apnea [5.23 (2.45-11.19)]. 78% of BP patients used at least one systemic immunosuppressant. There was no significant association between treatments for pemphigoid and any of the comorbidities.

Conclusions: Bullous pemphigoid patients need screening for comorbid health conditions even though treatment options do not seem to be associated with these comorbidities.

Citing Articles

Relationship between bullous pemphigoid and metabolic syndrome and its relevant traits: a bidirectional two-sample Mendelian randomization study.

Chen F, Zhang B, Li L Arch Dermatol Res. 2025; 317(1):180.

PMID: 39760936 DOI: 10.1007/s00403-024-03704-8.


Environmental triggers of pemphigus vulgaris and bullous pemphigoid: a case control study.

Stone C, Bak G, Oh D, Zhao C, Venugopal S, Kumar K Front Med (Lausanne). 2024; 11:1441369.

PMID: 39502648 PMC: 11537152. DOI: 10.3389/fmed.2024.1441369.


Systemic Implications of Bullous Pemphigoid: Bridging Dermatology and Internal Medicine.

Mashima E, Saito-Sasaki N, Sawada Y Diagnostics (Basel). 2024; 14(20).

PMID: 39451595 PMC: 11506695. DOI: 10.3390/diagnostics14202272.


Chronic disease associated with bullous pemphigoid risk: A systematic review and meta-analysis.

Siranart N, Chumpangern Y, Phutinart S, Pajareya P, Worapongpaiboon R, Winson C JAAD Int. 2024; 17:141-152.

PMID: 39444540 PMC: 11497425. DOI: 10.1016/j.jdin.2024.08.010.


Case report: Bullous pemphigoid combined with Sjögren's syndrome complicated by central nervous system infection.

Chen X, Chen J, Long K, Ding P, Li R, Zhi L Front Immunol. 2024; 15:1419054.

PMID: 39318633 PMC: 11420039. DOI: 10.3389/fimmu.2024.1419054.


References
1.
Gagnon R, Shuster J, Kaye M . Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis. J Clin Lab Immunol. 1983; 11(3):155-8. View